Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus
- Disease/Condition
- Diabetes,Diabetes Mellitus, Type 2
- Drug/Device/Intervention
- Semaglutide
- Study type
- Interventional
- Intervention type
- drug
- Primary sponsor
- Novo Nordisk A/S
- Location
- Andalusia,Anniston,Glendale,Phoenix,Tempe,Little Rock,La Jolla,Lincoln,Northridge,Edgewater,Maitland,Lawrenceville,Woodstock,Hutchinson,Lexington,Baltimore,Troy,Jefferson City,Albany,Smithtown,West Se, Austria,Canada,Japan,Norway,Puerto Rico,Russian Federation,United States of America
- Phase
- Phase 3
- Start date
- Mar 15, 2017
- End date
- Aug 06, 2018
- Enrollment
- 302 participants
Change in HbA1c
This trial is conducted in Asia, Europe and North America. The aim of the trial is to compare
 the effect of semaglutide s.c. 1.0 mg once-weekly versus placebo as add-on to sodium glucose
 co-transporter-2 inhibitor (SGLT-2i) monotherapy or in combination with either metformin or
 sulfonylurea on glycaemic control after 30 weeks of treatment in subjects with type 2
 diabetes. Subjects will remain on their pre-trial medication.
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT03086330
- Type
- Non-Device Trial
Access comprehensive clinical trial information for NCT03086330 through Pure Global AI's free database. This Phase 3 trial is sponsored by Novo Nordisk A/S and is currently Completed. The study focuses on Diabetes,Diabetes Mellitus, Type 2. Target enrollment is 302 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.